Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01052103 · ClinicalTrials.gov registry record · Phase 2
A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms
A Phase 2 study, sponsored by Denovo Biopharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 167
- Enrollment target
NCT01052103 is a Phase 2 study that has completed, run by Denovo Biopharma. The registered enrollment target is 167 participants.
The verdict
NCT01052103, a Phase 2 study, has completed, sponsored by Denovo Biopharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 167 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether LY2140023, when added to standard-of-care antipsychotic treatment, will improve negative symptoms.
Interventions
- DRUG Placebo
- DRUG Standard of Care
- DRUG LY2140023
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 167 participants |
| Start Date | 2010-01 |
| Est. Completion | 2012-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01052103
The ClinicalTrials.gov registry entry for NCT01052103 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 167 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Denovo Biopharma, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01052103 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01052103 about?
NCT01052103 is a clinical study titled "A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms". The purpose of this study is to determine whether LY2140023, when added to standard-of-care antipsychotic treatment, will improve negative symptoms.
What is the current status of trial NCT01052103?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 167 participants. The study started on 2010-01. Estimated completion is 2012-06.
What interventions are being tested in trial NCT01052103?
The interventions under investigation include: Placebo (DRUG), Standard of Care (DRUG), LY2140023 (DRUG).
Who is sponsoring clinical trial NCT01052103?
This trial is sponsored by Denovo Biopharma, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.